·The first topical transdermal patch in China for peripheral neuropathic pain ·Unique hydrogel technology ·Recommended as a first-line treatment in multiple authoritative guidelines in China, the US, and Europe ·Supported by the National Science and Technology Major Project for "Innovative Drug Research and Development"

*For contraindications and adverse reactions, please see the package insert

·First domestically produced cataplasm ·Leading brand in topical analgesics for many consecutive years, used for various types of inflammatory pain ·Recommended by 15 authoritative guidelines, including the "Guidelines for the Diagnosis and Treatment of Osteoarthritis" and the "Chinese Expert Consensus on the Management of Chronic Musculoskeletal Pain in the Elderly", and included in the "Guidelines for the Use of Commonly Used Therapeutic Drugs for Athletes (2020 Edition)" ·Selected as a national "Patent-Intensive Product" ·Served over 100 million patients cumulatively

*For contraindications and adverse reactions, please see the package insert

·The first small-molecule chemical drug in China for the treatment of lumbar spinal stenosis ·Improves neural microcirculation through a dual mechanism, breaking the technological bottleneck of ineffective oral administration of prostaglandin drugs ·Supported by the Industrial Strong Foundation Project of the Ministry of Industry and Information Technology

*For contraindications and adverse reactions, please see the package insert

·The first product of its kind in China to pass the consistency evaluation and be validated through Phase III clinical trials ·Recommended for chronic musculoskeletal pain in the "Chinese Guidelines for the Diagnosis and Treatment of Osteoarthritis (2024 Edition)"

*For contraindications and adverse reactions, please see the package insert

·First generic drug in China ·Served over 70 million patients with vein disorders cumulatively ·Recommended in over 20 guidelines and consensuses in the fields of venous, hemorrhoidal, and orthopedic diseases ·Winner of awards such as the "2024 China Pharmaceutical Brand List"

*For contraindications and adverse reactions, please see the package insert

·A disease-modifying drug for osteoarthritis ·Recommended by multiple Chinese and international guidelines for osteoarthritis ·Winner of awards such as the "Second Prize of Jiangsu Provincial Science and Technology Award", "Top Brand for Home Medicine Cabinets", "Xiding Potential Product Award", and "2024 Xipu Conference Brand List"

*For contraindications and adverse reactions, please see the package insert